{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:18:41Z","timestamp":1790518721203,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.medmal.2018.03.006","type":"journal-article","created":{"date-parts":[[2018,4,9]],"date-time":"2018-04-09T18:45:06Z","timestamp":1523299506000},"page":"495-502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Maribavir, brincidofovir and letermovir: Efficacy and safety of new antiviral drugs for treating cytomegalovirus infections"],"prefix":"10.1016","volume":"48","author":[{"given":"P.","family":"Frange","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Leruez-Ville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2018.03.006_bib0355","first-page":"526","article-title":"Seroprevalence of vaccine-preventable diseases and five other infectious diseases in France. Results of two national surveys 2008\u20132010","volume":"41-42","author":"Lepoutre","year":"2013","journal-title":"Bull Epidemiol Hebd"},{"key":"10.1016\/j.medmal.2018.03.006_bib0360","first-page":"638","article-title":"Cytomegalovirus infection and survival in lung transplant recipients","volume":"10","author":"Duncan","year":"1991","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.medmal.2018.03.006_bib0365","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1097\/00007890-199811270-00012","article-title":"Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients","volume":"66","author":"Ljungman","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.medmal.2018.03.006_bib0370","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S1083-8791(00)70010-3","article-title":"CMV antigenemia following bone marrow transplantation: risk factors and outcomes","volume":"6","author":"Osarogiagbon","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.medmal.2018.03.006_bib0375","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1086\/591532","article-title":"Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation","volume":"47","author":"San Juan","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2018.03.006_bib0380","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1473-3099(04)01202-2","article-title":"Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments","volume":"4","author":"Gandhi","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medmal.2018.03.006_bib0385","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.bbmt.2010.03.020","article-title":"Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease","volume":"16","author":"Cantoni","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.medmal.2018.03.006_bib0390","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.medmal.2018.03.006_bib0395","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/bmt.2008.162","article-title":"Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT","volume":"42","author":"Ljungman","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.medmal.2018.03.006_bib0400","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","article-title":"Updated international consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"96","author":"Kotton","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.medmal.2018.03.006_bib0405","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1056\/NEJM199609053351007","article-title":"Ganciclovir","volume":"335","author":"Crumpacker","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medmal.2018.03.006_bib0410","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2006.05.002","article-title":"Antiviral drugs for cytomegalovirus diseases","volume":"71","author":"Biron","year":"2006","journal-title":"Antiviral Res"},{"key":"10.1016\/j.medmal.2018.03.006_bib0415","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0166-3542(00)00139-X","article-title":"Genetic risks of antiviral nucleoside analogues \u2013\u00a0a survey","volume":"49","author":"Wutzler","year":"2001","journal-title":"Antiviral Res"},{"key":"10.1016\/j.medmal.2018.03.006_bib0420","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1469-0691.2000.00014.x","article-title":"Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis","volume":"6","author":"Piketty","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medmal.2018.03.006_bib0425","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/01.TP.0000164512.99703.AD","article-title":"Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients","volume":"79","author":"Wiltshire","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.medmal.2018.03.006_bib0430","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00467-003-1226-x","article-title":"Pharmacokinetics of ganciclovir in pediatric renal transplant recipients","volume":"18","author":"Zhang","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.medmal.2018.03.006_bib0435","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1399-3046.2006.00669.x","article-title":"Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children","volume":"11","author":"Vethamuthu","year":"2007","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.medmal.2018.03.006_bib0440","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ijantimicag.2010.11.033","article-title":"Ganciclovir treatment in children: evidence of subtherapeutic levels","volume":"37","author":"Luck","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medmal.2018.03.006_bib0445","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1399-3062.2009.00478.x","article-title":"Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients","volume":"12","author":"Pescovitz","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.medmal.2018.03.006_bib0450","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkq368","article-title":"Drug-resistant cytomegalovirus in transplant recipients: a French cohort study","volume":"65","author":"Hantz","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2018.03.006_bib0455","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/135965350901400512","article-title":"Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir","volume":"14","author":"Boivin","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.medmal.2018.03.006_bib0460","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1086\/519941","article-title":"Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients","volume":"45","author":"Li","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2018.03.006_bib0465","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/tid.12311","article-title":"The impact of drug-resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplant recipients: a prospective monitoring of UL97 and UL54 gene mutations","volume":"16","author":"Choi","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.medmal.2018.03.006_bib0470","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jit475","article-title":"High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation","volume":"209","author":"Shmueli","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.medmal.2018.03.006_bib0475","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0140-6736(00)02607-6","article-title":"Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants","volume":"356","author":"Limaye","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.medmal.2018.03.006_bib0480","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.antiviral.2008.11.003","article-title":"Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection","volume":"81","author":"Boutolleau","year":"2009","journal-title":"Antiviral Res"},{"key":"10.1016\/j.medmal.2018.03.006_bib0485","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.medmal.2018.03.006_bib0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M13-2729","article-title":"Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial","volume":"162","author":"Boeckh","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.medmal.2018.03.006_bib0495","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/00003088-200948060-00006","article-title":"Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements","volume":"48","author":"Perrottet","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.medmal.2018.03.006_bib0500","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1600-6143.2007.01910.x","article-title":"Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients","volume":"7","author":"Asberg","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.medmal.2018.03.006_bib0505","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00002030-199404000-00006","article-title":"Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG protocol 093). AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases","volume":"8","author":"Jacobson","year":"1994","journal-title":"AIDS"},{"key":"10.1016\/j.medmal.2018.03.006_bib0510","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jcv.2012.02.008","article-title":"Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection","volume":"54","author":"Boutolleau","year":"2012","journal-title":"J Clin Virol"},{"key":"10.1016\/j.medmal.2018.03.006_bib0515","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/10898540-000000000-00000","article-title":"New developments in the management of cytomegalovirus infection after solid organ transplantation","volume":"70","author":"Eid","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.medmal.2018.03.006_bib0520","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/TP.0b013e3181e94106","article-title":"Utility of leflunomide in the treatment of complex cytomegalovirus syndromes","volume":"90","author":"Avery","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.medmal.2018.03.006_bib0525","doi-asserted-by":"crossref","first-page":"60","DOI":"10.12659\/AOT.884035","article-title":"Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient \u2013\u00a0a case report","volume":"19","author":"Ciszek","year":"2014","journal-title":"Ann Transplant"},{"key":"10.1016\/j.medmal.2018.03.006_bib0530","doi-asserted-by":"crossref","first-page":"E243","DOI":"10.1111\/tid.12156","article-title":"Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature","volume":"15","author":"Verkaik","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.medmal.2018.03.006_bib0535","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood-2016-06-688432","article-title":"How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients","volume":"128","author":"El Chaer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.medmal.2018.03.006_bib0540","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/bmt.2012.46","article-title":"Evidence for clinical activity of artesunate in multidrug-resistant herpes simplex infection following HSCT","volume":"47","author":"Sellar","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.medmal.2018.03.006_bib0545","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.antiviral.2011.03.184","article-title":"Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation","volume":"90","author":"Wolf","year":"2011","journal-title":"Antiviral Res"},{"key":"10.1016\/j.medmal.2018.03.006_bib0550","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1086\/587106","article-title":"Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation","volume":"46","author":"Shapira","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2018.03.006_bib0555","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/cid\/ciq050","article-title":"Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection","volume":"52","author":"Lau","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2018.03.006_bib0560","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.antiviral.2013.10.014","article-title":"Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus","volume":"101","author":"Germi","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.medmal.2018.03.006_bib0565","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/clpt.2010.178","article-title":"Update on new antivirals under development for the treatment of double-stranded DNA virus infections","volume":"88","author":"Dropulic","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.medmal.2018.03.006_bib0570","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcv.2006.07.010","article-title":"Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet","volume":"37","author":"Drew","year":"2006","journal-title":"J Clin Virol"},{"key":"10.1016\/j.medmal.2018.03.006_bib0575","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1086\/518514","article-title":"Cytomegalovirus UL97 kinase mutations that confer maribavir resistance","volume":"196","author":"Chou","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.medmal.2018.03.006_bib0580","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1086\/653122","article-title":"Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir","volume":"202","author":"Strasfeld","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.medmal.2018.03.006_bib0585","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1128\/AAC.00577-06","article-title":"Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus","volume":"50","author":"Chou","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2018.03.006_bib0590","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1182\/blood-2007-11-121558","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study","volume":"111","author":"Winston","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.medmal.2018.03.006_bib0595","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medmal.2018.03.006_bib0600","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.coviro.2011.10.011","article-title":"Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed?","volume":"1","author":"Marty","year":"2011","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.medmal.2018.03.006_bib0605","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.transproceed.2013.01.082","article-title":"Maribavir use in practice for cytomegalovirus infection in French transplantation centers","volume":"45","author":"Alain","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1016\/j.medmal.2018.03.006_bib0610","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1111\/j.1600-6143.2012.04231.x","article-title":"Efficacy and safety of maribavir dosed at 100mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial","volume":"12","author":"Winston","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.medmal.2018.03.006_bib0615","series-title":"Maribavir versus valganciclovir for preemptive treatment of cytomegalovirus (CMV) viremia: a randomized, dose-ranging, phase 2 study among hematopoietic stem cell transplant (SCT) and solid organ transplant (SOT) recipients","author":"Maertens","year":"2016"},{"key":"10.1016\/j.medmal.2018.03.006_bib0620","series-title":"Maribavir for treatment of cytomegalovirus (CMV) infections resistant or refractory to ganciclovir or foscarnet in hematopoietic stem cell transplant (SCT) or solid organ transplant (SOT) recipients: a randomized, dose-ranging, double-blind, phase 2 study","author":"Papanicolaou","year":"2016"},{"key":"10.1016\/j.medmal.2018.03.006_bib0625","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1128\/AAC.00062-13","article-title":"Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus","volume":"57","author":"James","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2018.03.006_bib0630","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medmal.2018.03.006_bib0635","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.bbmt.2016.01.009","article-title":"Brincidofovir for prevention of cytomegalovirus (CMV) after allogeneic hematopoietic cell transplantation (HCT) in CMV-seropositive patients: a randomized, double-blind, placebo-controlled, parallel-group phase 3 trial [abstract]","volume":"22","author":"Marty","year":"2016","journal-title":"Biol Bone Marrow Transpl"},{"key":"10.1016\/j.medmal.2018.03.006_bib0640","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.antiviral.2016.08.024","article-title":"Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: a single-center experience","volume":"134","author":"El-Haddad","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.medmal.2018.03.006_bib0645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcv.2016.07.021","article-title":"The use of brincidofovir for the treatment of mixed dsDNA viral infection","volume":"83","author":"Camargo","year":"2016","journal-title":"J Clin Virol"},{"key":"10.1016\/j.medmal.2018.03.006_bib0650","first-page":"3624146","article-title":"Brincidofovir use after foscarnet crystal nephropathy in a kidney transplant recipient with multiresistant cytomegalovirus infection","volume":"2017","author":"Vial","year":"2017","journal-title":"Case Rep Transplant"},{"key":"10.1016\/j.medmal.2018.03.006_bib0655","doi-asserted-by":"crossref","first-page":"e5226","DOI":"10.1097\/MD.0000000000005226","article-title":"Case report: brincidofovir-induced reversible severe acute kidney injury in 2 solid-organ transplants for treatment of cytomegalovirus infection","volume":"95","author":"Faure","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.medmal.2018.03.006_bib0660","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2018.03.006_bib0665","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1128\/AAC.05908-11","article-title":"In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses","volume":"56","author":"Marschall","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2018.03.006_bib0670","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiv352","article-title":"Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228)","volume":"213","author":"Lischka","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.medmal.2018.03.006_bib0675","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.antiviral.2016.06.008","article-title":"Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to letermovir","volume":"132","author":"Lischka","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.medmal.2018.03.006_bib0680","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medmal.2018.03.006_bib0685","series-title":"43rd Annual Meeting of the European Society for Blood and Marrow Transplantation","article-title":"Letermovir for prevention of cytomegalovirus infections: results from a phase III randomized, double-blinded, placebo-controlled trial in adult allogeneic hematopoietic cell transplant recipients","author":"Ljungman","year":"2017"},{"key":"10.1016\/j.medmal.2018.03.006_bib0690","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/tri.12225","article-title":"Preemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study","volume":"27","author":"Stoelben","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.medmal.2018.03.006_bib0695","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1600-6143.2011.03530.x","article-title":"First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246","volume":"11","author":"Kaul","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.medmal.2018.03.006_bib0700","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X17307874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X17307874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:16:38Z","timestamp":1759972598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X17307874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":70,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0399077X17307874"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2018.03.006","relation":{},"ISSN":["0399-077X"],"issn-type":[{"value":"0399-077X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maribavir, brincidofovir and letermovir: Efficacy and safety of new antiviral drugs for treating cytomegalovirus infections","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2018.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}